Sunday 11 October 2026
Export all VXRT data to Excel Powerpack
VAXART, INC.
VXRT Healthcare Biotechnology
VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
0.43
0.00
0.00%
Follow VXRT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
3.81 | 4.07 | 5.83 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.61 | 0.57 | 0.34 | 0.56 | |
P/FCF ratio |
4.42 | 9.92 | 10.64 | 0.00 | |
P/Operating CF |
53.18 | (71.47) | 2.63 | 31.76 | |
P/B ratio |
1.79 | 1.56 | 0.92 | 3.08 | |
Price to Tangible BV |
1.96 | 1.69 | 1.00 | 4.28 | |
EV/Sales |
0.35 | 0.34 | 0.08 | 0.37 | |
EV/EBITDA |
1.87 | 1.91 | 0.68 | 0.00 | |
EV/Operating CF |
2.50 | 5.70 | 2.33 | (1.81) | |
EV/FCF |
2.54 | 5.87 | 2.37 | (1.80) | |
Quick Ratio |
1.52 | 1.54 | 1.33 | 0.68 | |
Current Ratio |
1.60 | 1.71 | 1.57 | 0.69 | |
Net Debt/EBITDA |
5.11 | (9.77) | (1.12) | 5.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.48 | 1.51 | 1.35 | 0.79 | |
Operating CF/Net income |
(0.21) | (0.40) | 0.56 | (0.32) | |
Capex/Depreciation |
(0.04) | (0.42) | 0.00 | (0.05) | |
Interest Coverage |
(24.48) | 10.24 | 101.51 | (12.85) | |
Research and Development Expense of Revenue |
124.16% | 74.98% | 43.31% | 104.88% | |
Selling, General and Administrative Expense of Revenue |
24.29% | 11.83% | 3.52% | 5.91% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
4.75% | 3.78% | 1.65% | 2.79% | |
Graham Net Nets |
0.23 | 0.31 | 0.47 | (0.79) | |
Graham Number |
1.11 | 1.15 | 0.72 | 0.00 | |
Earnings Yield |
26.23% | 24.59% | 17.14% | (63.89%) | |
Free Cash Flow Yield |
22.61% | 10.08% | 9.40% | (36.98%) | |
Revenue per Share |
0.11 | 0.16 | 0.45 | 0.32 | |
Operating CF per Share |
0.01 | (0.01) | 0.13 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.01) | 0.13 | 0.01 | |
Cash per Share |
0.26 | 0.25 | 0.28 | 0.13 | |
Shareholders Equity per Share |
0.34 | 0.39 | 0.38 | 0.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.34 | 0.39 | 0.38 | 0.12 | |
Free Cash Flow |
2.75 | (2.50) | 30.66 | 2.48 | |
Working Capital |
43.58 | 54.86 | 49.37 | (51.93) | |
Capital Expenditures |
(0.02) | (0.44) | 0.00 | (0.11) | |
Net Current Asset Value |
33.88 | 45.77 | 37.84 | (64.86) | |
EV/EBIT |
2.14 | 2.28 | 0.99 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
3.73 | 3.84 | 4.46 | 0.00 | |
| Other line items | |||||
Average Receivables |
44.03 | 36.85 | 31.66 | 44.81 | |
Average Payables |
13.79 | 20.40 | 14.23 | 27.80 | |
Average Assets |
164.64 | 169.31 | 176.23 | 187.83 | |
Average Common Equity |
57.62 | 69.87 | 73.36 | 47.60 |
Columns are period end dates